BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer's and Parkinson's Disease
(firmenpresse) - NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwire) -- 03/08/13 -- BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today a poster presentation of clinical and scientific data at the 11th International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2013) this week in Florence, Italy ().
"We are excited to be presenting our NurOwn™ technology at this important meeting," said Alon Natanson, Chief Executive Officer of BrainStorm Cell Therapeutics. "The AD/PD Conference brings international medical professionals together for a dynamic scientific program revealing cutting-edge research and discoveries diagnosing, preventing, and treating neurodegenerative diseases. We believe that our groundbreaking data on NurOwn™ will be well received by the attendees."
In the coming months BrainStorm will be making a number of presentations at various international medical and research conferences as the scientific communities in Europe and the US are closely following the company's progress with its clinical development program.
NurOwn is an autologous, adult stem cell therapy technology that differentiates bone marrow-derived mesenchymal stem cells (MSC) into specialized, neuron-supporting cells. These neuron-supporting cells (known as "MSC-NTF" cells) secrete neurotrophic, or nerve-growth, factors for PROTECTION of existing motor neurons, PROMOTION of motor neuron growth, and RE-ESTABLISHMENT of nerve-muscle interaction. The ability to differentiate mesenchymal stem cells into MSC-NTF cells, and confirmation of their activity and potency before transplantation, makes NurOwn a first-of-its-kind approach for treating neurodegenerative diseases. More information about NurOwn™ can be found at .
BrainStorm Cell Therapeutics, Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University. For more information, visit the company's website at .
Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at . These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.
CONTACTS
BrainStorm Cell Therapeutics Inc.
Mr. Alon Natanson
CEO
Phone: +972-3-9236384
LifeSci Advisors, LLC
Michael Rice
Founding Partner
646-597-6979
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 08.03.2013 - 10:09 Uhr
Sprache: Deutsch
News-ID 1205039
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY and PETACH TIKVAH, ISRAEL
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 163 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"BrainStorm Cell Therapeutics Presents at the 11th International Conference on Alzheimer's and Parkinson's Disease
"
steht unter der journalistisch-redaktionellen Verantwortung von
BrainStorm Cell Therapeutics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
